Post Pandemic, US Cardiovascular Death Rate Continues Upward Trajectory

New research confirms what public health leaders have been fearing: the significant uptick in the cardiovascular disease (CVD) death rate that began in 2020 has continued. The continuing trend reverses improvements achieved in the decade before the COVID-19 pandemic to reduce mortalities from heart disease and stroke, the leading causes of death in the United States. The findingsopens in new tab/window are reported in the American Journal of Preventive Medicineopens in new tab/window, published by Elsevier.

Investigators from the US Centers for Disease Control and Prevention (CDC) and Northwestern University Feinberg School of Medicine analyzed information from more than 10 million death certificates of US adults (aged 35+ years) whose deaths occurred between 2010 and 2022.

Rebecca C. Woodruff, PhD, MPH, Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Chamblee, GA, explained, “We were concerned about the emerging evidence that chronic disease outcomes worsened during the first two years of the COVID-19 pandemic. This was unfortunately the case with heart disease and stroke, which had been improving before the pandemic. We wanted to understand whether the concerning trends were temporary or whether they continued through 2022.”

Looking at trends each year from 2010 to 2022, the researchers’ findings show that the death rates from cardiovascular disease rose by 9.3% from 2020 through 2022, in contrast to a decline of 8.9% from 2010 to 2019. There were more than 228,000 more CVD deaths from 2020-2022 than would be expected had the pre-2020 trends continued. The reversal was evident across many ages, both sexes, and several race and ethnicity groups.

Dr. Woodruff characterized the resultsas an enduring setback in population health, evident after the public health emergency had largely stabilized. She pointed to several possible explanations for the increases:

• The pandemic disrupted access to healthcare for many people, which may have resulted in delays in detecting and treating chronic or acute heart disease.

• The crisis also disrupted many aspects of daily life that may have made it harder for people to do the things that prevent heart disease, including managing blood pressure, eating well, being physically active, quitting tobacco, getting healthy sleep, managing weight, controlling cholesterol, and managing blood sugar.

• An emerging body of evidence also suggests that people who have had COVID-19 are at increased risk for new or worsening heart disease, which may have contributed to the subsequent increase in cardiovascular death rates.

Dr. Woodruff noted, “Research to understand the drivers of these increases in CVD mortality rates can help guide clinicaland public health approaches to prevent, detect, and treat CVD. Reprioritizing prevention and management of CVD is an essential first step.”

She highlighted several federal initiatives that focus on decreasing the burden of CVD: WISE WOMAN (Well-integrated Screening and Evaluation for Women Across the Nation, Paul Coverdell National Acute Stroke Program, and Million Hearts^®, adding that “the magnitude of the setbacks in CVD mortality and the range of affected subgroups speak to the need for broader prevention efforts moving forward.”

Notes for editors

The article is“Trends in Cardiovascular Disease Mortality Rates and Excess Deaths, 2010–2022,” by Rebecca C. Woodruff, PhD, MPH, Xin Tong, MPH, Sadiya S. Khan, MD, Nilay S. Shah, MD, Sandra L. Jackson, PhD, Fleetwood Loustalot, PhD, and Adam S. Vaughan, PhD, MPH (https://doi.org/10.1016/j.amepre.2023.11.009opens in new tab/window).It appears online in advance of the American Journal of Preventive Medicine, volume 66, issue 4 (April 2024), published by Elsevier.

Full text of this article is available to credentialed journalists upon request; contact Jillian B. Morgan at +1 734 936 1590 or [email protected]opens in new tab/window. Journalists wishing to interview the authors should contact Trayce Leak at [email protected]opens in new tab/window.

Co-author Nilay Shah, MD, receives research support from the NHLBI (K23HL157766).

The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

About the American Journal of Preventive Medicine

The American Journal of Preventive Medicineopens in new tab/window is the official journal of the American College of Preventive Medicineopens in new tab/window and the Association for Prevention Teaching and Researchopens in new tab/window. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials. www.ajpmonline.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.